188 related articles for article (PubMed ID: 33633310)
1. Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer.
Yashiro M; Kuroda K; Masuda G; Okuno T; Miki Y; Yamamoto Y; Sera T; Sugimoto A; Kushiyama S; Nishimura S; Togano S; Ohira M
Sci Rep; 2021 Feb; 11(1):4698. PubMed ID: 33633310
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor receptor 2 IIIc as a therapeutic target for colorectal cancer cells.
Matsuda Y; Hagio M; Seya T; Ishiwata T
Mol Cancer Ther; 2012 Sep; 11(9):2010-20. PubMed ID: 22778155
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts.
Zhao WM; Wang L; Park H; Chhim S; Tanphanich M; Yashiro M; Kim KJ
Clin Cancer Res; 2010 Dec; 16(23):5750-8. PubMed ID: 20670946
[TBL] [Abstract][Full Text] [Related]
4. Altered expression of fibroblast growth factor receptor 2 isoform IIIc: relevance to endometrioid adenocarcinoma carcinogenesis and histological differentiation.
Peng WX; Kudo M; Fujii T; Teduka K; Naito Z
Int J Clin Exp Pathol; 2014; 7(3):1069-76. PubMed ID: 24696723
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer.
Han N; Kim MA; Lee HS; Kim WH
Pathobiology; 2015; 82(6):269-79. PubMed ID: 26516773
[TBL] [Abstract][Full Text] [Related]
6. Fgfr1 and the IIIc isoform of Fgfr2 play critical roles in the metanephric mesenchyme mediating early inductive events in kidney development.
Sims-Lucas S; Cusack B; Baust J; Eswarakumar VP; Masatoshi H; Takeuchi A; Bates CM
Dev Dyn; 2011 Jan; 240(1):240-9. PubMed ID: 21128305
[TBL] [Abstract][Full Text] [Related]
7. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival.
Ahn S; Lee J; Hong M; Kim ST; Park SH; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Jung SH; Kang WK; Kim KM
Mod Pathol; 2016 Sep; 29(9):1095-103. PubMed ID: 27230412
[TBL] [Abstract][Full Text] [Related]
8. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
Nagatsuma AK; Aizawa M; Kuwata T; Doi T; Ohtsu A; Fujii H; Ochiai A
Gastric Cancer; 2015 Apr; 18(2):227-38. PubMed ID: 24626858
[TBL] [Abstract][Full Text] [Related]
9. Convergent signalling through Fgfr2 regulates divergent craniofacial morphogenesis.
Veistinen L; Aberg T; Rice DP
J Exp Zool B Mol Dev Evol; 2009 Jun; 312B(4):351-60. PubMed ID: 19205045
[TBL] [Abstract][Full Text] [Related]
10. Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer.
Inokuchi M; Murase H; Otsuki S; Kawano T; Kojima K
World J Surg Oncol; 2017 Jan; 15(1):2. PubMed ID: 28056982
[TBL] [Abstract][Full Text] [Related]
11. The IIIc alternative of Fgfr2 is a positive regulator of bone formation.
Eswarakumar VP; Monsonego-Ornan E; Pines M; Antonopoulou I; Morriss-Kay GM; Lonai P
Development; 2002 Aug; 129(16):3783-93. PubMed ID: 12135917
[TBL] [Abstract][Full Text] [Related]
12. Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancer.
Minashi K; Yamada T; Hosaka H; Amagai K; Shimizu Y; Kiyozaki H; Sato M; Soeda A; Endo S; Ishida H; Kamoshida T; Sakai Y; Shitara K
Jpn J Clin Oncol; 2021 Oct; 51(10):1523-1533. PubMed ID: 34258618
[TBL] [Abstract][Full Text] [Related]
13. FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation.
Betts G; Valentine H; Pritchard S; Swindell R; Williams V; Morgan S; Griffiths EA; Welch I; West C; Womack C
Virchows Arch; 2014 Feb; 464(2):145-56. PubMed ID: 24306956
[TBL] [Abstract][Full Text] [Related]
14. Targeting Fibroblast Growth Factor Receptor (FGFR) with BGJ398 in a Gastric Cancer Model.
Schmidt K; Moser C; Hellerbrand C; Zieker D; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
Anticancer Res; 2015 Dec; 35(12):6655-65. PubMed ID: 26637881
[TBL] [Abstract][Full Text] [Related]
15. The nonsense-mediated decay pathway and mutually exclusive expression of alternatively spliced FGFR2IIIb and -IIIc mRNAs.
Jones RB; Wang F; Luo Y; Yu C; Jin C; Suzuki T; Kan M; McKeehan WL
J Biol Chem; 2001 Feb; 276(6):4158-67. PubMed ID: 11042206
[TBL] [Abstract][Full Text] [Related]
16. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
17. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets.
Lee HJ; Seo AN; Park SY; Kim JY; Park JY; Yu JH; Ahn JH; Gong G
Ann Surg Oncol; 2014 May; 21(5):1561-8. PubMed ID: 24385208
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a New Scirrhous Gastric Cancer Cell Line with FGFR2 Overexpression, OCUM-14.
Okuno T; Yashiro M; Masuda G; Togano S; Kuroda K; Miki Y; Hirakawa K; Ohsawa M; Wanibuchi H; Ohira M
Ann Surg Oncol; 2019 Apr; 26(4):1093-1102. PubMed ID: 30652228
[TBL] [Abstract][Full Text] [Related]
19. FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohort.
Schrumpf T; Behrens HM; Haag J; Krüger S; Röcken C
PLoS One; 2022; 17(2):e0264011. PubMed ID: 35167603
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cells with FGFR2 expression might be useful to identify patients with existing FGFR2-overexpressing tumor.
Kuroda K; Yashiro M; Miki Y; Sera T; Yamamoto Y; Sugimoto A; Nishimura S; Kushiyama S; Togano S; Okuno T; Ohira M
Cancer Sci; 2020 Dec; 111(12):4500-4509. PubMed ID: 32946655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
